| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Rino Rappuoli | Q2154243 |
| P2093 | author name string | Ennio De Gregorio | |
| Oretta Finco | |||
| Matthew J. Bottomley | |||
| Ugo D’Oro | |||
| P2860 | cites work | MF59 Mediates Its B Cell Adjuvanticity by Promoting T Follicular Helper Cells and Thus Germinal Center Responses in Adult and Early Life. | Q41337351 |
| Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice | Q42218132 | ||
| Cross-neutralization of four paramyxoviruses by a human monoclonal antibody | Q42275949 | ||
| Secondary immunization generates clonally related antigen-specific plasma cells and memory B cells. | Q42671244 | ||
| An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus | Q47957009 | ||
| A rapid and efficient single-cell manipulation method for screening antigen-specific antibody-secreting cells from human peripheral blood. | Q51564288 | ||
| Structural vaccinology starts to deliver | Q57988219 | ||
| Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group | Q77300551 | ||
| Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells | Q21562507 | ||
| A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals | Q24560010 | ||
| Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies | Q24561905 | ||
| A highly conserved neutralizing epitope on group 2 influenza A viruses | Q24630467 | ||
| Rapid cloning of high-affinity human monoclonal antibodies against influenza virus | Q24644672 | ||
| Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses | Q24649949 | ||
| Antibody recognition of a highly conserved influenza virus epitope | Q24655932 | ||
| Self-assembling protein nanoparticles in the design of vaccines | Q26767097 | ||
| Structural and Computational Biology in the Design of Immunogenic Vaccine Antigens | Q26777382 | ||
| Antibody responses to envelope glycoproteins in HIV-1 infection | Q26991572 | ||
| Serology in the 21st century: the molecular-level analysis of the serum antibody repertoire | Q26997997 | ||
| Antibodies in HIV-1 vaccine development and therapy | Q27011574 | ||
| Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus | Q27644501 | ||
| Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies | Q27644515 | ||
| Structural basis of respiratory syncytial virus neutralization by motavizumab | Q27659146 | ||
| Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens | Q37456354 | ||
| A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program | Q37471668 | ||
| Identification and characterization of the constituent human serum antibodies elicited by vaccination. | Q37587683 | ||
| Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission | Q37708741 | ||
| Prospects for defined epitope vaccines for respiratory syncytial virus | Q37721415 | ||
| Systems analysis of adaptive immunity by utilization of high-throughput technologies | Q37875449 | ||
| New approaches to HIV vaccine development | Q38521826 | ||
| Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming | Q39761197 | ||
| Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection | Q40173380 | ||
| Design and Characterization of Epitope-Scaffold Immunogens That Present the Motavizumab Epitope from Respiratory Syncytial Virus | Q27667750 | ||
| Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers | Q27667876 | ||
| Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding | Q27670829 | ||
| A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins | Q27671165 | ||
| Highly Conserved Protective Epitopes on Influenza B Viruses | Q27671404 | ||
| Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors | Q27677104 | ||
| Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody | Q27677570 | ||
| Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus | Q27680499 | ||
| A common solution to group 2 influenza virus neutralization | Q27680873 | ||
| Proof of principle for epitope-focused vaccine design | Q27681593 | ||
| Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection | Q27701887 | ||
| A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen | Q27701889 | ||
| Whole-genome random sequencing and assembly of Haemophilus influenzae Rd | Q27860765 | ||
| Protein Crystallography in Vaccine Research and Development | Q28087528 | ||
| Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41 | Q28236154 | ||
| Edward Jenner's Inquiry; a bicentenary analysis | Q28297101 | ||
| Antigenic Characterization of the HCMV gH/gL/gO and Pentamer Cell Entry Complexes Reveals Binding Sites for Potently Neutralizing Human Antibodies | Q28550400 | ||
| HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers | Q28647225 | ||
| Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target | Q29547347 | ||
| Broad neutralization coverage of HIV by multiple highly potent antibodies | Q29615361 | ||
| Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody | Q29618366 | ||
| Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 | Q29619511 | ||
| Predominant autoantibody production by early human B cell precursors | Q29619656 | ||
| Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis | Q29619821 | ||
| Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangements | Q30364187 | ||
| Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine | Q30388038 | ||
| A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin | Q30406095 | ||
| Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies | Q30430925 | ||
| Germinal center dynamics revealed by multiphoton microscopy with a photoactivatable fluorescent reporter | Q30498133 | ||
| Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies | Q33328393 | ||
| A method for identification of HIV gp140 binding memory B cells in human blood | Q33394829 | ||
| Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex | Q33558361 | ||
| Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys | Q33597744 | ||
| Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. | Q33860721 | ||
| Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. | Q33892877 | ||
| High throughput cellular screens to interrogate the human T and B cell repertoires | Q33907471 | ||
| Antibody-secreting B cells in HIV infection | Q33914185 | ||
| Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia | Q34049077 | ||
| Convergent antibody signatures in human dengue | Q34060276 | ||
| Edward Jenner and the eradication of smallpox | Q34066116 | ||
| Reverse vaccinology | Q34069770 | ||
| Immune response to pneumococcal polysaccharides 4 and 14 in elderly and young adults: analysis of the variable heavy chain repertoire | Q34111761 | ||
| Vaccines: science, health, longevity, and wealth | Q34120026 | ||
| Influenza vaccines for the future | Q34150283 | ||
| B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study | Q34273373 | ||
| Respiratory syncytial virus infection in elderly and high-risk adults | Q34414401 | ||
| Structure and function of respiratory syncytial virus surface glycoproteins. | Q34414405 | ||
| Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface | Q34473958 | ||
| Identification of antigen-specific B cell receptor sequences using public repertoire analysis | Q34749062 | ||
| Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies | Q34753135 | ||
| Antibodies, viruses and vaccines | Q34810301 | ||
| Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals | Q34962766 | ||
| Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody | Q35170702 | ||
| Antibody-based protection against HIV infection by vectored immunoprophylaxis | Q35658856 | ||
| Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention | Q35778982 | ||
| Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes | Q35943392 | ||
| Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions | Q35982791 | ||
| The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens | Q35989852 | ||
| Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice | Q36159067 | ||
| HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. | Q36345558 | ||
| A virus-like particle that elicits cross-reactive antibodies to the conserved stem of influenza virus hemagglutinin. | Q36363177 | ||
| Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning | Q36459907 | ||
| Fully human monoclonal antibodies from antibody secreting cells after vaccination with Pneumovax®23 are serotype specific and facilitate opsonophagocytosis | Q36565432 | ||
| Isolation of human monoclonal antibodies from peripheral blood B cells | Q36833296 | ||
| Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. | Q36961578 | ||
| Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation | Q36977531 | ||
| Structure-based antigen design: a strategy for next generation vaccines | Q37314536 | ||
| A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities | Q37444686 | ||
| The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity | Q37448171 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunology | Q101929 |
| vaccine | Q134808 | ||
| biomedical investigative technique | Q66648976 | ||
| vaccine engineering | Q14861085 | ||
| P304 | page(s) | 469-81 | |
| P577 | publication date | 2016-04-04 | |
| P1433 | published in | Journal of Experimental Medicine | Q3186912 |
| P1476 | title | Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design | |
| P478 | volume | 213 |
| Q58735723 | A Gene-Based Positive Selection Detection Approach to Identify Vaccine Candidates Using as a Test Case Protozoan Pathogen |
| Q94491384 | A cutting-edge immunoinformatics approach for design of multi-epitope oral vaccine against dreadful human malaria |
| Q63984735 | A highly expressed intestinal cysteine protease of Ancylostoma ceylanicum protects vaccinated hamsters from hookworm infection |
| Q55053671 | A qualitatively validated mathematical-computational model of the immune response to the yellow fever vaccine. |
| Q52317335 | An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus. |
| Q92965786 | Antibodies against Plasmodium falciparum malaria at the molecular level |
| Q96641551 | Application of System Biology to Explore the Association of Neprilysin, Angiotensin-Converting Enzyme 2 (ACE2), and Carbonic Anhydrase (CA) in Pathogenesis of SARS-CoV-2 |
| Q38768895 | Applying proteomics to tick vaccine development: where are we? |
| Q57817461 | Bacterial Vaccine Antigen Discovery in the Reverse Vaccinology 2.0 Era: Progress and Challenges |
| Q58781552 | Beyond Hot Spots: Biases in Antibody Somatic Hypermutation and Implications for Vaccine Design |
| Q98188950 | Bioinformatics analysis of epitope-based vaccine design against the novel SARS-CoV-2 |
| Q63246442 | Boosting subdominant neutralizing antibody responses with a computationally designed epitope-focused immunogen |
| Q39197155 | Burkholderia pseudomallei and Burkholderia mallei vaccines: Are we close to clinical trials? |
| Q55340953 | Changing Priorities in Vaccinology: Antibiotic Resistance Moving to the Top. |
| Q55003572 | Computational Modeling of Hepatitis C Virus Envelope Glycoprotein Structure and Recognition. |
| Q90650313 | Cross-Reactive Bactericidal Antimeningococcal Antibodies Can Be Isolated From Convalescing Invasive Meningococcal Disease Patients Using Reverse Vaccinology 2.0. |
| Q40200645 | CryoEM Structure of an Influenza Virus Receptor-Binding Site Antibody-Antigen Interface |
| Q48095992 | Crystal structure reveals vaccine elicited bactericidal human antibody targeting a conserved epitope on meningococcal fHbp. |
| Q41912569 | Crystal structures of human Fabs targeting the Bexsero meningococcal vaccine antigen NHBA |
| Q92629953 | Current trends in targeted therapy for drug-resistant infections |
| Q49849737 | Deploy vaccines to fight superbugs. |
| Q92184345 | Detection and activation of HIV broadly neutralizing antibody precursor B cells using anti-idiotypes |
| Q47158624 | EMA and EFSA Joint Scientific Opinion on measures to reduce the need to use antimicrobial agents in animal husbandry in the European Union, and the resulting impacts on food safety (RONAFA) |
| Q49886229 | Ecology and evolution of Mycobacterium tuberculosis. |
| Q42377340 | Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model |
| Q40047469 | Eliminating acute rheumatic fever and rheumatic heart disease |
| Q47155273 | Extended low-resolution structure of a Leptospira antigen offers high bactericidal antibody accessibility amenable to vaccine design |
| Q38829564 | Fighting Neisseria meningitidis: past and current vaccination strategies |
| Q90696470 | First International Precision Vaccines Conference: Multidisciplinary Approaches to Next-Generation Vaccines |
| Q53056444 | Genome-wide identification of novel vaccine candidates for Plasmodium falciparum malaria using integrative bioinformatics approaches. |
| Q54233532 | Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines. |
| Q41936503 | Glycans Function as Anchors for Antibodies and Help Drive HIV Broadly Neutralizing Antibody Development |
| Q92237228 | Immunoinformatics Approach to Design a Novel Epitope-Based Oral Vaccine Against Helicobacter pylori |
| Q90249670 | Immunoinformatics and Vaccine Development: An Overview |
| Q90466213 | Induction of cross-reactive HIV-1 specific antibody responses by engineered V1V2 immunogens with reduced conformational plasticity |
| Q50208609 | Innovation Partnership for a Roadmap on Vaccines in Europe (IPROVE): A vision for the vaccines of tomorrow. |
| Q56515654 | Innovative approaches to track lymph node germinal center responses to evaluate development of broadly neutralizing antibodies in human HIV vaccine trials |
| Q93063721 | Lessons for general vaccinology research from attempts to develop an HIV vaccine |
| Q39062411 | Mathematical modeling based on ordinary differential equations: A promising approach to vaccinology |
| Q40109161 | Nanoparticle orientationally displayed antigen epitopes improve neutralizing antibody level in a model of porcine circovirus type 2. |
| Q63362961 | Oligomannose Glycopeptide Conjugates Elicit Antibodies Targeting the Glycan Core Rather than Its Extremities |
| Q40470909 | One vaccinology? Overcoming challenges in vaccine development. |
| Q93081608 | Peptide-Based Vaccination for Antibody Responses Against HIV |
| Q62630863 | Peptides for Infectious Diseases: From Probe Design to Diagnostic Microarrays |
| Q47700986 | Perspectives in allergen immunotherapy: 2017 and beyond |
| Q59599346 | Postgenomic Approaches and Bioinformatics Tools to Advance the Development of Vaccines against Bacteria of the Complex |
| Q64115920 | Prioritization of potential vaccine targets using comparative proteomics and designing of the chimeric multi-epitope vaccine against Pseudomonas aeruginosa |
| Q37621530 | Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies |
| Q64983102 | Protein and Glycan Mimicry in HIV Vaccine Design. |
| Q104105760 | Rapid developability assessments to formulate recombinant protein antigens as stable, low-cost, multi-dose vaccine candidates: Case-study with non-replicating rotavirus (NRRV) vaccine antigens |
| Q59806879 | Recent Trends in System-Scale Integrative Approaches for Discovering Protective Antigens Against Mycobacterial Pathogens |
| Q92652148 | Reverse vaccinology and subtractive genomics reveal new therapeutic targets against Mycoplasma pneumoniae: a causative agent of pneumonia |
| Q97885825 | Second career of a biosynthetic enzyme: Lumazine synthase as a virus-like nanoparticle in vaccine development |
| Q24672537 | Some vexations that challenge viral immunology |
| Q89446935 | Structure-based immunogen design-leading the way to the new age of precision vaccines |
| Q90169965 | Systems Biological Analysis of Immune Response to Influenza Vaccination |
| Q30238729 | Systems serology for evaluation of HIV vaccine trials |
| Q94502896 | São Paulo School of Advanced Sciences on Vaccines: an overview |
| Q92487060 | TIPICO IX: report of the 9th interactive infectious disease workshop on infectious diseases and vaccines |
| Q58691534 | Targeting Difficult Protein-Protein Interactions with Plain and General Computational Approaches |
| Q100466517 | Technological approaches to streamline vaccination schedules, progressing towards single-dose vaccines |
| Q60301819 | Technologies to address antimicrobial resistance |
| Q57094341 | The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen |
| Q55518743 | Towards conformational fidelity of a quaternary HIV-1 epitope: computational design and directed evolution of a minimal V1V2 antigen. |
| Q39170404 | Towards functional antibody-based vaccines to prevent pre-erythrocytic malaria infection |
| Q92538472 | Using Omics Technologies and Systems Biology to Identify Epitope Targets for the Development of Monoclonal Antibodies Against Antibiotic-Resistant Bacteria |
| Q40130441 | Using homology modeling to interrogate binding affinity in neutralization of ricin toxin by a family of single domain antibodies |
| Q92564603 | Vaccine Evolution and Its Application to Fight Modern Threats |
| Q36413834 | Vaccine candidate discovery for the next generation of malaria vaccines. |
| Q51416013 | Vaccines Meet Big Data: State-of-the-Art and Future Prospects. From the Classical 3Is ("Isolate-Inactivate-Inject") Vaccinology 1.0 to Vaccinology 3.0, Vaccinomics, and Beyond: A Historical Overview. |
| Q40346058 | What Are the Most Powerful Immunogen Design Vaccine Strategies? Reverse Vaccinology 2.0 Shows Great Promise |
| Q58804243 | When designing vaccines, consider the starting material: the human B cell repertoire |
| Q30829948 | Whither vaccines? |
| Q96230739 | [Vaccine of the future] |
Search more.